Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...

CAMBRIDGE, Mass. and SINGAPORE, March 03, 2026 (GLOBE NEWSWIRE) -- Cirrus Therapeutics today announced several business and pipeline updates to support its growth as a leading global ocular immunology ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early ...